The following IPOs are expected to price this week:
Berry Plastics Group (BERY), which manufactures plastic goods and containers for consumer applications, plans to raise $500 million by offering 29.4 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, Berry Plastics Group would command a market value of $2.0 billion. Berry Plastics Group, which was founded in 1967, booked $4.8 billion in sales over the last 12 months. The Evansville, IN-based company plans to list on the NYSE under the symbol BERY. BofA Merrill Lynch, Citi, Barclays and Deutsche Bank are the joint bookrunners on the deal.
Dave & Buster's Entertainment (PLAY), which operates 60 casual dining restaurants with large arcade areas, plans to raise $100 million by offering 7.7 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Dave & Buster's Entertainment would command a market value of $364 million. Dave & Buster's Entertainment, which was founded in 1982, booked $576 million in sales over the last 12 months. The Dallas, TX-based company plans to list on the NASDAQ under the symbol PLAY. Goldman Sachs, Jefferies & Co. and Piper Jaffray are the joint bookrunners on the deal.
Fleetmatics Group (FLTX), which is a leading SaaS provider of fleet management solutions, plans to raise $125 million by offering 7.8 million shares at a price range of $15.00 to $17.00. At the midpoint of the proposed range, Fleetmatics Group would command a market value of $588 million. Fleetmatics Group, which was founded in 2004, booked $108 million in sales over the last 12 months. The Dublin, Ireland-based company plans to list on the NYSE under the symbol FLTX. Barclays and BofA Merrill Lynch are the joint bookrunners on the deal.
GlobeImmune (GBIM), which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, plans to raise $60 million by offering 5.0 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, GlobeImmune would command a market value of $207 million. GlobeImmune, which was founded in 1995, booked $9 million in sales over the last 12 months. The Louisville, CO-based company plans to list on the NASDAQ under the symbol GBIM. Wells Fargo Securities and Piper Jaffray are the joint bookrunners on the deal.
Javelin Mortgage Investment (JMI), an ARMOUR-managed REIT newly formed to acquire mortgage-related assets, plans to raise $125 million by offering 6.3 million shares at a price of $20.00. At the midpoint of the proposed range, Javelin Mortgage Investment would command a market value of $130 million. Javelin Mortgage Investment was founded in 2012. The Vero Beach, FL-based company plans to list on the NYSE under the symbol JMI. Deutsche Bank, Citi, Barclays and Credit Suisse are the joint bookrunners on the deal.
LifeLock (LOCK), an online provider of identity theft protection services, plans to raise $165 million by offering 15.7 million shares at a price range of $9.50 to $11.50. At the midpoint of the proposed range, LifeLock would command a market value of $981 million. LifeLock, which was founded in 2005, booked $228 million in sales over the last 12 months. The Tempe, AZ-based company plans to list on the NYSE under the symbol LOCK. Goldman Sachs, BofA Merrill Lynch and Deutsche Bank are the joint bookrunners on the deal.
Luxfer Holdings (LXFR), a global materials firm specializing in aluminum, magnesium and zirconium, plans to raise $104 million by offering 8.0 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Luxfer Holdings would command a market value of $341 million. Luxfer Holdings, which was founded in 1996, booked $534 million in sales over the last 12 months. The Salford, United Kingdom-based company plans to list on the NYSE under the symbol LXFR. Credit Suisse and Jefferies & Co. are the joint bookrunners on the deal.
Regulus Therapeutics (RGLS), an early stage biotech developing microRNAs treatments for multiple serious diseases, plans to raise $50 million by offering 4.5 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Regulus Therapeutics would command a market value of $239 million. Regulus Therapeutics, which was founded in 2007, booked $14 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol RGLS. Lazard Capital Markets, Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
Last week, there were 3 IPO pricings. Qualys (QLYS), which provides cloud-based IT security and compliance software solutions, was the week's winner, ending up 18% from its IPO price.
